Rheumatology
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
From the Journals
Adverse event rates compared for colchicine, NSAIDs when starting allopurinol for gout
Patients receiving prophylactic colchicine or NSAIDs with initiation of allopurinol for gout have more adverse events than those who receive no...
From the Journals
More evidence shows COVID-19’s link to risk for autoimmune disease
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several...
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...
Commentary
Rheumatoid arthritis: Five things to know
A healthier lifestyle is associated with a reduced risk of developing rheumatoid arthritis.
From the Journals
PET scan at diagnosis may help to predict aneurysm risk in patients with giant cell arteritis
Patients with aortic inflammation detected by PET were at greater risk for developing aortic aneurysms, particularly thoracic aortic aneurysms.
News from the FDA/CDC
FDA approves first tocilizumab biosimilar
Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.
Feature
Tapering lupus drugs in stable patients: Large study outlines risks, benefits
A recent multinational, observational cohort study found that drug tapering warrants careful consideration of risks and benefits and is best...
Conference Coverage
Patients with rheumatism have premature immune system aging
Researchers have studied how the T-cell aging process translates into metabolic reprogramming of the T cells in patients with rheumatoid arthritis...
From the Journals
Mortality in ankylosing spondylitis: CV disease, drug abuse are big contributors
Heart failure and renal disease were the strongest contributing comorbidities to mortality in hospitalized patients with ankylosing spondylitis....
Conference Coverage
Sotatercept tied to disease modification in pulmonary arterial hypertension
Data unveiled at the European Respiratory Society International Congress 2023, held in Milan, suggest that sotatercept treatment has the capacity...